Concepedia

Tom Rozema

TR

Statistics

Publications

39

Citations

12.9K

H-Index

23

Active since

2005

Affiliations

Instituut Verbeeten(Current)

Radboud University Nijmegen

Leiden University Medical Center

University Medical Center Utrecht

Catharina Ziekenhuis

Tom Rozema is an author at Instituut Verbeeten specializing in medicine, oncology, and esophageal cancer.

ORCID

Publications per year

2005–2023

39

Publications

39

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

Pieter van Hagen, Maarten C.C.M. Hulshof, J. Jan B. van Lanschot et al. · New England Journal of Medicine · 2012 · 5.5K citations · Full text

, , +14

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

Joël Shapiro, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · The Lancet Oncology · 2015 · 2.6K citations

, , +17

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer, Esmée A. Dijkstra, Boudewijn van Etten et al. · The Lancet Oncology · 2020 · 1.6K citations · Full text

, , +17

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Ben M. Eyck, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · Journal of Clinical Oncology · 2021 · 772 citations · Full text

, , +17

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Annemieke Cats, Edwin P. M. Jansen, Nicole C.T. van Grieken et al. · The Lancet Oncology · 2018 · 576 citations

, , +17

1–5 of 39